Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads
This article was originally published in Start Up
With big Phase III failures heating debate about the amyloid hypothesis, small biotechs must convince investors that their early research is pointed in the right direction, and larger ones must design clinical trials with care. We profile four Alzheimer's-focused start-ups in this issue: AlzProtect, Axerion Therapeutics, Cognition Therapuetics and Galantos Pharma.
You may also be interested in...
Biotech Equity Crowdfunding Gets A Head Start Overseas
Can crowdfunding fill the biotech capital gap? In the US, new services are jockeying at the starting gate even though the government’s final rules won’t be ready soon, while in Europe the experiment has begun in earnest.
Investors Lend Satori $15 Million, Hoping It Converts To An Alzheimer's Treatment
The venture-backed Cambridge, Mass. firm says it can get its small-molecule gamma-secretase modulator into the clinic next year.
Alzheimer's Dx: An Essential Piece of the Puzzle
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.